Arax Advisory Partners’s Tourmaline Bio TRML Stock Holding History

Arax Advisory Partners’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-47	Closed	-$2.25K	–	4526
2025 Q3	$2.25K	Sell	47 -5	-10%	-$139	﹤0.01%	3091
2025 Q2	$832	Buy	+52	New	+$842	﹤0.01%	2841
2025 Q1	–	Sell	-30	Closed	-$609	–	3038
2024 Q4	$609	Buy	+30	New	+$755	﹤0.01%	2291

Arax Advisory Partners's TRML Position: Q4 2025 in Review

Arax Advisory Partners sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 47 shares — an estimated $2.25K sold.

Arax Advisory Partners first reported a position in TRML in Q4 2024 and held it in 3 quarters. The position peaked at $2.25K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Arax Advisory Partners reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Arax Advisory Partners sold 47 Tourmaline Bio shares in Q4 2025, an estimated $2.25K.
Arax Advisory Partners first reported a position in Tourmaline Bio in Q4 2024 and held it in 3 quarters.
Arax Advisory Partners's Tourmaline Bio position peaked at $2.25K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.